Deals
Valeant Buys Female Libido-Drug Maker Sprout for $1 Billion
Valeant to Buy Female Libido-Drug Maker Sprout
This article is for subscribers only.
Valeant Pharmaceuticals International Inc. agreed to pay about $1 billion in cash for Sprout Pharmaceuticals Inc., the U.S. drugmaker that this week received approval to sell a pill for low libido in women.
Valeant will give closely held Sprout a share of future profits if certain milestones are achieved, according to a statement on Thursday. The companies declined to disclose how the milestone payments would be structured.